Literature DB >> 7845668

Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.

M Theile1, S Hartmann, H Scherthan, W Arnold, W Deppert, R Frege, F Glaab, W Haensch, S Scherneck.   

Abstract

A number of candidate tumor suppressor genes located on the human chromosome 17 are thought to have a role to play in the development of breast cancer. In addition to the p53 gene on 17p13.1 and the BRCA1 gene mapped to 17q12-21, other chromosomal regions for tumor suppressor genes have been suggested to exist on 17p13.3 and both the central and the distal parts of 17q, although definitive functional proof of their involvement in breast cancer tumorigenesis is still lacking. In this report we show that microcell transfer of a human chromosome 17 into wild-type p53 breast cancer cells CAL51 results in loss of tumorigenicity and anchorage-independent growth, changes in cell morphology and a reduction of cell growth rates of the neo-selected microcell hybrids. In the hybrid cells, which express the p53 wild-type protein, only the p- and the distal parts of the q arm of donor chromosome 17 are transferred. Thus, our results provide functional evidence for the presence of one or more tumor suppressor gene(s) on chromosome 17, which are distinct from the p53 and the BRCA1 genes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7845668

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

Review 1.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Authors:  Kathryn J Chavez; Sireesha V Garimella; Stanley Lipkowitz
Journal:  Breast Dis       Date:  2010

2.  Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ.

Authors:  K E Munn; R A Walker; L Menasce; J M Varley
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

3.  Tumor suppressor activity of profilin requires a functional actin binding site.

Authors:  Nina Wittenmayer; Burkhard Jandrig; Martin Rothkegel; Kathrin Schlüter; Wolfgang Arnold; Wolfgang Haensch; Siegfried Scherneck; Brigitte M Jockusch
Journal:  Mol Biol Cell       Date:  2004-02-06       Impact factor: 4.138

4.  Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1.

Authors:  J Janke; K Schlüter; B Jandrig; M Theile; K Kölble; W Arnold; E Grinstein; A Schwartz; L Estevéz-Schwarz; P M Schlag; B M Jockusch; S Scherneck
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

5.  Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene.

Authors:  D S Liscia; R Morizio; T Venesio; C Palenzona; M Donadio; R Callahan
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

6.  Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.

Authors:  G Nicoll; D N Crichton; H E McDowell; N Kernohan; T R Hupp; A M Thompson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

7.  Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.

Authors:  J Edwards; P Duncan; J J Going; K M Grigor; A D Watters; J M Bartlett
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.